» Articles » PMID: 39397188

Dopaminergic Neuron Metabolism: Relevance for Understanding Parkinson's Disease

Overview
Journal Metabolomics
Publisher Springer
Specialty Endocrinology
Date 2024 Oct 13
PMID 39397188
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Dopaminergic neurons from the substantia nigra pars compacta (SNc) have a higher susceptibility to aging-related degeneration, compared to midbrain dopaminergic cells present in the ventral tegmental area (VTA); the death of dopamine neurons in the SNc results in Parkinson´s disease (PD). In addition to increased loss by aging, dopaminergic neurons from the SNc are more prone to cell death when exposed to genetic or environmental factors, that either interfere with mitochondrial function, or cause an increase of oxidative stress. The oxidation of dopamine is a contributing source of reactive oxygen species (ROS), but this production is not enough to explain the differences in susceptibility to degeneration between SNc and VTA neurons.

Aim Of Review: In this review we aim to highlight the intrinsic differences between SNc and VTA dopamine neurons, in terms of gene expression, calcium oscillations, bioenergetics, and ROS responses. Also, to describe the changes in the pentose phosphate pathway and the induction of apoptosis in SNc neurons during aging, as related to the development of PD.

Key Scientific Concepts Of Review: Recent work showed that neurons from the SNc possess intrinsic characteristics that result in metabolic differences, related to their intricate morphology, that render them more susceptible to degeneration. In particular, these neurons have an elevated basal energy metabolism, that is required to fulfill the demands of the constant firing of action potentials, but at the same time, is associated to higher ROS production, compared to VTA cells. Finally, we discuss how mutations related to PD affect metabolic pathways, and the related mechanisms, as revealed by metabolomics.

Citing Articles

Unraveling the role of Nrf2 in dopaminergic neurons: a review of oxidative stress and mitochondrial dysfunction in Parkinson's disease.

Kaur M, Aran K Metab Brain Dis. 2025; 40(2):123.

PMID: 39932604 DOI: 10.1007/s11011-025-01552-7.


The Crucial Role of the Blood-Brain Barrier in Neurodegenerative Diseases: Mechanisms of Disruption and Therapeutic Implications.

Kim S, Jung U, Kim S J Clin Med. 2025; 14(2).

PMID: 39860392 PMC: 11765772. DOI: 10.3390/jcm14020386.

References
1.
Cleeland C, Pipingas A, Scholey A, White D . Neurochemical changes in the aging brain: A systematic review. Neurosci Biobehav Rev. 2019; 98:306-319. DOI: 10.1016/j.neubiorev.2019.01.003. View

2.
Kaddurah-Daouk R, Krishnan K . Metabolomics: a global biochemical approach to the study of central nervous system diseases. Neuropsychopharmacology. 2008; 34(1):173-86. DOI: 10.1038/npp.2008.174. View

3.
Wishart D . Emerging applications of metabolomics in drug discovery and precision medicine. Nat Rev Drug Discov. 2016; 15(7):473-84. DOI: 10.1038/nrd.2016.32. View

4.
Hu M, Taylor-Robinson S, Chaudhuri K, Bell J, Labbe C, Cunningham V . Cortical dysfunction in non-demented Parkinson's disease patients: a combined (31)P-MRS and (18)FDG-PET study. Brain. 2000; 123 ( Pt 2):340-52. DOI: 10.1093/brain/123.2.340. View

5.
Kish S, Shannak K, Rajput A, Deck J, Hornykiewicz O . Aging produces a specific pattern of striatal dopamine loss: implications for the etiology of idiopathic Parkinson's disease. J Neurochem. 1992; 58(2):642-8. DOI: 10.1111/j.1471-4159.1992.tb09766.x. View